See more : Styrenix Performance Materials Limited (STYRENIX.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Cartica Acquisition Corp (CITEU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cartica Acquisition Corp, a leading company in the Shell Companies industry within the Financial Services sector.
- The Gummy Project Inc. (GUMYF) Income Statement Analysis – Financial Results
- mCloud Technologies Corp. (MCLDW) Income Statement Analysis – Financial Results
- Otsuka Corporation (OSUKF) Income Statement Analysis – Financial Results
- EXMceuticals Inc. (EXM.CN) Income Statement Analysis – Financial Results
- NuVim, Inc. (NUVM) Income Statement Analysis – Financial Results
Cartica Acquisition Corp (CITEU)
About Cartica Acquisition Corp
Cartica Acquisition Corp does not have any significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to identify and complete a business combination in the technology sector in India. Cartica Acquisition Corp was incorporated in 2021 and is based in Washington, the District of Columbia.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.04M | 2.19M | 0.00 |
| Gross Profit | -2.04M | -2.19M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.04M | 2.19M | 292.79K |
| Other Expenses | 0.00 | 2.19M | 0.00 |
| Operating Expenses | 0.00 | 2.19M | 292.79K |
| Cost & Expenses | 2.04M | 2.19M | 292.79K |
| Interest Income | 0.00 | 3.21M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.46M | 2.19M | 292.79K |
| EBITDA | 8.42M | 14.73M | 24.40K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.04M | -2.19M | -292.79K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.42M | 14.73M | 0.00 |
| Income Before Tax | 6.38M | 12.54M | -292.79K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -14.73M | -268.10K |
| Net Income | 6.38M | 27.27M | -292.79K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.32 | 0.95 | -0.01 |
| EPS Diluted | 0.32 | 0.95 | -0.01 |
| Weighted Avg Shares Out | 19.94M | 28.75M | 27.83M |
| Weighted Avg Shares Out (Dil) | 19.94M | 28.75M | 27.83M |
U.S. IPO Weekly Recap: Biotechs Ring In The New Year In A 4 IPO Week
Source: https://incomestatements.info
Category: Stock Reports